Neuroimmune dysfunction is thought to promote the development of several acute and chronic complications in spinal cord injury (SCI) patients. Putative roles for adrenal stress hormones and catecholamines are increasingly being recognized, yet how these adversely affect peripheral tissue homeostasis and repair under SCI conditions remains elusive. Here, we investigated their influence in a mouse model of SCI with acquired neurogenic heterotopic ossification. We show that spinal cord lesions differentially influence muscular regeneration in a level-dependent manner and through a complex multi-step process that creates an osteopermissive environment within the first hours of injury. This cascade of events is shown to critically involve adrenergic signals and drive the acute release of the neuropeptide, substance P. Our findings generate new insights into the kinetics and processes that govern SCI-induced deregulations in skeletal muscle homeostasis and regeneration, thereby aiding the development of sequential therapeutic strategies that can prevent or attenuate neuromusculoskeletal complications in SCI patients.
Get full access to this article
View all access options for this article.
References
1.
KrauseJ.S., and SaundersL.L. (2011). Health, secondary conditions, and life expectancy after spinal cord injury. Arch. Phys. Med. Rehabil. 92, 1770–1775.
2.
NebahatS., AkkuşS., and Gülçin UğurluF. (2015). Chronic complications of spinal cord injury. World J. Orthop. 6, 24–33.
3.
YoussefianT., SapenaR., CarlierR., BosC., DenormandieA., DenysP., CormierA., and BandelierM. (2004). Nodular osteochondrogenic activity in soft tissue surrounding osteoma in neurogenic para osteo-arthropathy: morphological and immunohistochemical study. BMC Musculoskelet. Disord. 5, 46.
4.
HernandezA.M., FornerJ.V., de la FuenteT., GonzalezC., and MiroR. (1978). The para-articular ossifications in our paraplegics and tetraplegics: a survey of 704 patients. Paraplegia, 16, 272–275.
5.
WittenbergR.H., PeschkeU., and BötelU. (1992). Heterotopic ossification after spinal cord injury. Epidemiology and risk factors. J. Bone Joint Surg. Br. 74, 215–218.
6.
CitakM., SueroE.M., BackhausM., AachM., GodryH., MeindlR., and SchildhauerT.A. (2012). Risk factors for heterotopic ossification in patients with spinal cord injury: a case-control study of 264 patients. Spine, 37, 1953–1957.
7.
CarpentierV.T., SalgaM., GatinL., GenêtF., and PaquereauJ. (2021). Early diagnosis of heterotopic ossification among patients admitted to a neurological post intensive care rehabilitation unit. Eur. J. Phys. Rehabil. Med. doi: 10.2373/6/S1973-9087.21.06589-8.
ShoreE.M., and KaplanF.S. (2010). Inherited human diseases of heterotopic bone formation. Nat. Rev. Rheumatol. 6, 518–527.
10.
OhlmeierM., KrennV., ThiesenD.M., SandifordN.A., GehrkeT., and CitakM. (2019). Heterotopic ossification in orthopaedic and trauma surgery: a histopathological ossification score. Sci. Rep. 9, 18401.
11.
LeviB., JayakumarP., GiladiA., JupiterJ.B., RingD.C., KowalskeK., GibranN.S., HerndonD., SchneiderJ.C., and RyanC.M. (2015). Risk factors for the development of heterotopic ossification in seriously burned adults: a National Institute on Disability, Independent Living and Rehabilitation Research burn model system database analysis. J. Trauma Acute Care Surg. 79, 870–876.
12.
RossierA.B., BussatP., InfanteF., ZenderR., CourvoisierB., MuhelmG., DonathA., VaseyH., TaillardW., LagierR., GabbianiG., BaudC.A., PouezatJ.A., VeryJ.M., and HachenH.J. (1973). Current facts of para-osteo-arthropathy (POA). Paraplegia, 11, 38–78.
13.
TanakaT., RossierA.B., HusseyR.W., AhnbergD.S., and TrevesS. (1977). Quantitative assessment of para-osteo-arthropathy and its maturation on serial radionuclide bone images. Radiology, 123, 217–221.
14.
DiaS., ElgazzarA.H., and CollierB.D. (2002). Heterotopic ossification. J. Nucl. Med. 43, 346–353.
15.
van KuijkA.A., GeurtsA.C.H., and van KuppeveltH.J.M. (2002). Neurogenic heterotopic ossification in spinal cord injury. Spinal Cord, 40, 313–326.
16.
McCarthyE.F., and SundaramM. (2005). Heterotopic ossification: a review. Skeletal Radiol. 34, 609–619.
17.
Vanden BosscheL., and VanderstraetenG. (2005). Heterotopic ossification: a review. J. Rehabil. Med. 37, 129–136.
18.
GenêtF., JourdanC., SchnitzlerA., LautridouC., GuillemotD., JudetT., PoiraudeauS., and DenormandieP. (2011). Troublesome heterotopic ossification after central nervous system damage: a survey of 570 surgeries. PLoS One, 6, e16632.
19.
SullivanM.P., TorresS.J., MehtaS., and AhnJ. (2013). Heterotopic ossification after central nervous system trauma: a current review. Bone Joint Res. 2, 51–57.
20.
OrzelJ.A., and RuddT.G. (1985). Heterotopic bone formation: clinical, laboratory, and imaging correlation. J. Nucl. Med. 26, 125–132.
21.
FoleyK.L., HebelaN., KeenanM.A., and PignoloR.J. (2018). Histopathology of periarticular non-hereditary heterotopic ossification. Bone, 109, 65–70.
22.
AlexanderK.A., TsengH.W., SalgaM., GenêtF., and LevesqueJ.P. (2020). When the nervous system turns skeletal muscles into bones: how to solve the conundrum of neurogenic heterotopic ossification. Curr. Osteoporos. Rep. 18, 6666–6676.
23.
HuangH., ChengW.X., HuY.P., ChenJ.H., ZhengZ.T., and ZhangP. (2018). Relationship between heterotopic ossification and traumatic brain injury: why severe traumatic brain injury increases the risk of heterotopic ossification. J. Orthop. Translat. 12, 16–25.
24.
SakellariouV.I., GrigoriouE., MavrogenisA.F., SoucacosP.N., and PapagelopoulosP.J. (2012). Heterotopic ossification following traumatic brain injury and spinal cord injury: insight into the etiology and pathophysiology. J. Musculoskelet. Neuronal Interact. 12, 230–240.
25.
DaviesO.W., LiuY., PlayerD.J., MartinN.R.W., GroverL.M., and LewisM.P. (2017). Defining the balance between regeneration and pathological ossification in skeletal muscle following traumatic injury. Front. Physiol. 8, 194.
26.
JuarezJ.K., WenkeJ.C., and RiveraJ.C. (2018). Treatments and preventative measures for trauma-induced heterotopic ossification: a review. Clin. Transl. Sci. 11, 365–370.
27.
DebaudC., SalgaM., BegotL., HolyX., ChedikM., de l'EscalopierN., TorossianF., LevesqueJ.P., LatailladeJ.J., Le Bousse-KerdilèsM.C., and GenêtF. (2017). Peripheral denervation participates in heterotopic ossification in a spinal cord injury model. PLoS One, 12, e0182454.
28.
GenêtF., KulinaI., VaquetteC., TorossianF., MillardS., PettitA.R., SimsN.A., AnginotA., GuertonB., WinklerI.G., BarbierV., LatailladeJ.J., Le Bousse-KerdilèsM.C., HutmacherD.W., and LevesqueJ.P. (2015). Neurological heterotopic ossification following spinal cord injury is triggered by macrophage-mediated inflammation in muscle. J. Pathol. 236, 229–240.
29.
TorossianF., GuertonB., AnginotA., AlexanderK.A., DesterkeC., SoaveS., TsengH.W., AroucheN., BoutinL., KulinaI., SalgaM., JoseB., PettitA.R., ClayD., RochetN., VlachosE., GenetG., DebaudC., DenormandieP., GenetF., SimsN.A., BanzetS., LevesqueJ.P., LatailladeJ.J., and Le Bousse-KerdilèsM.C. (2017). Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. JCI Insight, 2, e96034.
30.
AlexanderK.A., TsengH.W., FlemingW., JoseB., SalgaM., KulinaI., MillardS.M., PettitA.R., GenêtF., and LevesqueJ.P. (2019). Inhibition of JAK1/2 tyrosine kinases reduces neurogenic heterotopic ossification after spinal cord injury. Front. Immunol. 10, 377.
31.
KilkennyC., BrowneW.J., CuthillI.C., EmersonM., and AltmanD.G. (2010). Improving bioscience research reporting: the ARRIVE Guidelines for Reporting Animal Research. PLoS Biol. 8, e1000412.
32.
PrüssH., TedeschiA., ThiriotA., LynchL., LoughheadS.M., StutteS., MazoI.B., KoppM.A., BrommerB., BlexC., GeurtzL.C., LiebscherT., NiedeggenA., DirnaglU., BradkeF., VolzM.S., DeVivoM.J., ChenY., von AndrianU.H., and SchwabJ.M. (2017). Spinal cord injury-induced immunodeficiency is mediated by a sympathetic-neuroendocrine adrenal reflex. Nat. Neurosci. 20, 1549–1559.
33.
ScheffS.W., RabchevskyA.G., FugacciaI., MainJ.A., and LumppJ.E. (2003). Experimental modeling of spinal cord injury: characterization of a force-defined injury device. J. Neurotrauma, 20, 179–193.
34.
van EerdJ.E.M., VegtE., WetzelsJ.F.M., RusselF.G.M., MasereeuwR., CorstensF.H.M., OyenW.J.G., and BoermanO.C. (2006). Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J. Nucl. Med. 47, 528–533.
35.
BurkholderT., FoltzC., KarlssonE., LintonC.G., and SmithJ.M. (2012). Health evaluation of experimental laboratory mice. Curr. Protoc. Mouse Biol. 2, 145–165.
36.
KatayamaY., BattistaM., KaoW.M., HidalgoA., PeiredA.J., ThomasS.A., and FrenetteP.S. (2006). Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell, 124, 407–421.
37.
PalkóvitsM. (2010). Sympathoadrenal system: neural arm of the stress response, in: Encyclopedia of Neuroscience, 1st ed. L.R. Squire (ed). Elsevier: Amsterdam, The Netherlands, pps. 679–684.
38.
GodoyL.D., RossignoliM.T., Delfino-PereiraP., Garcia-CairascoN., and de Lima UmeokaE.H. (2018). A comprehensive overview on stress neurobiology: basic concepts and clinical implications. Front. Behav. Neurosci. 12, 127.
39.
SchulzeJ., VogelgesangA., and DresselA. (2014). Catecholamines, steroids and immune alterations in ischemic stroke and other acute diseases. Aging Dis. 5, 327–339.
40.
Biering-SørensenF., Biering-SørensenT., LiuN., MalmqvistL., WechtJ.M., and KrassioukovA. (2018). Alterations in cardiac autonomic control in spinal cord injury. Auton. Neurosci. 209, 4–18.
41.
TaylorM.P., WrennP., and O'DonnellA.D. (2017). Presentation of neurogenic shock within the emergency department. Emerg. Med. J. 34, 157–162.
42.
OberbeckR. (2006). Catecholamines: physiological immunomodulators during health and illness. Curr. Med. Chem. 13, 1979–1989.
43.
QiaoG., BucsekM.J., WinderN.M., ChenM., GiridharanT., OlejniczakS.H., HylanderB.L., and RepaskyE.A. (2019). β-Adrenergic signaling blocks murine CD8+ T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress. Cancer Immunol. Immunother. 68, 11–22.
44.
BarnesM.A., CarsonM.J., and NairM.G. (2015). Non-traditional cytokines: how catecholamines and adipokines influence macrophages in immunity, metabolism and the central nervous system. Cytokine, 72, 210–219.
45.
KostrzewaR.M., and JacobowitzD.M. (1974). Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev. 26, 199–288.
46.
JoersV., DilleyK., RahmanS., JonesC., ShultzJ., SimmonsH., and EmborgM.E. (2014). Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates. PLoS One, 9, e104850.
47.
RyallJ.G., ChurchJ.E. and LynchG.S. (2010). Novel role for ß-adrenergic signalling in skeletal muscle growth, development and regeneration. Clin. Exp. Pharmacol. Physiol. 37, 397–401.
48.
LeonardA.V., ManavisJ., BlumbergsP.C., and VinkR. (2014). Changes in Substance P and NK1 receptor immunohistochemistry following human spinal cord injury. Spinal Cord, 52, 17–23.
49.
RieggerT., ConradS., SchluesenerH.J., KapsH.P., BadkeA., BaronC., GersteinJ., DietzK., AbdizahdehM., and SchwabJ.M. (2009). Immune depression syndrome following human spinal cord injury (SCI): a pilot study. Neuroscience, 158, 1194–1199.
50.
PopovichP.G., and McTigueD. (2009). Damage control in the nervous system: beware the immune system in spinal cord injury. Nat. Med. 15, 736–737.
51.
SunX., JonesZ.B., ChenX.M., ZhouL., SoK.F., and RenY. (2016). Multiple organ dysfunction and systemic inflammation after spinal cord injury: a complex relationship. J. Neuroinflammation, 13, 260.
52.
HenningsenJ., RigboltK.T.G., BlagoevB., PedersenB.K., and KratchmarovaI. (2010). Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol. Cell. Proteomics, 9, 2482–2496.
53.
LeeJ.H., and JunH.S. (2019). Role of myokines in regulating skeletal muscle mass and function. Front. Physiol. 10, 42.
54.
MageriuV., ManoleE., BastianA.E., and StaniceanuF. (2020). Role of myokines in myositis pathogenesis and their potential to be new therapeutic targets in idiopathic inflammatory myopathies. J. Immunol. Res. 2020, 9079083.
55.
FrewinD.B., LevittM., MyersS.J., and DowneyJ.A. (1973). Catecholamine responses in paraplegia. Spinal Cord, 11, 238–244.
56.
JungW.C., LevesqueJ.P., and RuitenbergM.J. (2017). It takes nerve to fight back: the significance of neural innervation of the bone marrow and spleen for immune function. Semin. Cell Dev. Biol. 61, 60–70.
57.
XiaH., LiX., GaoW., FuX., FangR.H., ZhangL., and ZhangK. (2018). Tissue repair and regeneration with endogenous stem cells. Nat. Rev. Mater. 3, 174–193.
58.
SorkinM., HuberA.K., HwangC., CarsonW.F., MenonR., LiJ., VasquezK., PaganiC., PatelN., LiS., VisserN.D., NiknafsY., LoderS., ScolaM., NyczD., GallagherK., McCauleyL.K., XuJ., JamesA.W., AgarwalS., KunkelS., MishinaY., and LeviB. (2020). Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healing. Nat. Commun. 11, 722.
59.
QiaoG., ChenM., BucsekM.J., RepaskyE.A., and HylanderB.L. (2018). Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response. Front. Immunol. 9, 164.
60.
KimT.H., LyC., ChristodoulidesA., NowellC.J., GunningP.W., SloanE.K., and RowatA.C. (2019). Stress hormone signaling through β-adrenergic receptors regulates macrophage mechanotype and function. FASEB J. 33, 3997–4006.
61.
LynchG.S., and RyallJ.G. (2008). Role of β-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol. Rev. 88, 729–767.
HarveyA.L. (1985). Cardiotoxins from cobra venoms: possible mechanisms of action. J. Toxicol. 4, 41–69.
64.
Lin ShiauS.Y., HuangM.C., and LeeC.Y. (1976). Mechanism of action of cobra cardiotoxin in the skeletal muscle. J. Pharmacol. Exp. Ther. 196, 758–770.
65.
O'ConnorT.M., O'ConnellJ., O'BrienD.I., GoodeT., BredinC.P., and ShanahanF. (2004). The role of substance P in inflammatory disease. J. Cell. Physiol. 201, 167–180.
66.
LewisK.M., TurnerR.J., and VinkR. (2013). Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system. Int. J. Inflam. 2013, 578480.
67.
TuzmenC., VerdelisK., WeissL., and CampbellP. (2018). Crosstalk between substance P and calcitonin gene-related peptide during heterotopic ossification in murine achilles tendon. J. Orthop. Res. 36, 1444–1455.
68.
SpringerJ., and FischerA. (2003). Substance P-induced pulmonary vascular remodelling in precision cut lung slices. Eur. Respir. J. 22, 596–601.
69.
LinleyJ.E., OoiL., PettingerL., KirtonH., BoyleJ.P., PeersC., and GamperN. (2012). Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons. Proc. Natl. Acad. Sci. U. S. A. 109, E1578–E1586.
70.
AvilaG., de la RosaJ.A., Monsalvo-VillegasA., and Montiel-JaenM.G. (2019). Ca2+ channels mediate bidirectional signaling between sarcolemma and sarcoplasmic reticulum in muscle cells. Cells, 9, 55.
71.
MaggiC.A., PatacchiniR., RoveroP., and GiachettiA. (1993). Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol. 13, 23–93.
72.
WangQ., ChuC.H., QianL., ChenS.H., WilsonB., OyarzabalE., JiangL., AliS., RobinsonB., KimH.C., and HongJ.S. (2014). Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase. J. Neurosci. 34, 12490–12503.
73.
GrimbyG., BrobergC., KrotkiewskaI., and KrotkiewskiM. (1976). Muscle fiber composition in patients with traumatic cord lesion. Scand. J. Rehabil. Med. 8, 37–42.
74.
ClarkJ.M., and FindlayD.M. (2017). Musculoskeletal health in the context of spinal cord injury. Curr. Osteoporos. Rep. 15, 433–442.
75.
TalmadgeR.J., CastroM.J., AppleD.F. and DudleyG.A. (2002). Phenotypic adaptations in human muscle fibers 6 and 24 wk after spinal cord injury. J. Appl. Physiol. 92, 147–154.
76.
HeppleR.T. (2016). Impact of aging on mitochondrial function in cardiac and skeletal muscle. Free Radic. Biol. Med. 98, 177–186.
77.
LiY., SunJ., WuR., BaiJ., HouY., ZengY., ZhangY., WangX., WangZ., and MengX. (2020). Mitochondrial MPTP: a novel target of ethnomedicine for stroke treatment by apoptosis inhibition. Front. Pharmacol. 11, 352.
78.
GorgeyA.S., WittO., O'BrienL., CardozoC., ChenQ., LesnefskyE.J., and GrahamZ.A. (2019). Mitochondrial health and muscle plasticity after spinal cord injury. Eur. J. Appl. Physiol. 119, 315–331.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
